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Heart failureIn cardiac muscle, a number of posttranslational protein modiﬁcations can alter the function of the Ca2+ release
channel of the sarcoplasmic reticulum (SR), also known as the ryanodine receptor (RyR). During every heartbeat
RyRs are activated by the Ca2+-induced Ca2+ release mechanism and contribute a large fraction of the Ca2+
required for contraction. Some of the posttranslational modiﬁcations of the RyR are known to affect its gating
and Ca2+ sensitivity. Presently, research in a number of laboratories is focused on RyR phosphorylation, both
by PKA and CaMKII, or on RyR modiﬁcations caused by reactive oxygen and nitrogen species (ROS/RNS). Both
classes of posttranslational modiﬁcations are thought to play important roles in the physiological regulation of
channel activity, but are also known to provoke abnormal alterations during various diseases. Only recently it
was realized that several types of posttranslational modiﬁcations are tightly connected and form synergistic
(or antagonistic) feed-back loops resulting in additive and potentially detrimental downstream effects. This
review summarizes recent ﬁndings on such posttranslational modiﬁcations, attempts to bridge molecular with
cellular ﬁndings, and opens a perspective for future work trying to understand the ramiﬁcations of crosstalk in
these multiple signaling pathways. Clarifying these complex interactions will be important in the development
of novel therapeutic approaches, since this may form the foundation for the implementation of multi-pronged
treatment regimes in the future. This article is part of a Special Issue entitled: Cardiomyocyte Biology: Cardiac
Pathways of Differentiation, Metabolism and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
In cardiac muscle, ryanodine receptors (RyRs) serve as Ca2+ release
channels of the intracellular Ca2+ store, the sarcoplasmic reticulum
(SR). Thereby, they provide a large fraction of the Ca2+ required to
initiatemuscle contraction frombeat to beat. They are normally activat-
ed by a small amount of Ca2+ entering into cardiac muscle cells from
the extracellular space, via voltage-dependent Ca2+ channels. This
Ca2+-induced Ca2+ release (CICR) from the SR is the mechanism
which ampliﬁes the Ca2+ signal and governs excitation–contraction
(EC) coupling by activation of RyRs (for review see [1])./calmodulin-dependent protein kina
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l rights reserved.Research on the RyR, both on its structure and function, has
been carried out over the last decades using multiple experimental
approaches and techniques to overcome the difﬁculty of examining
a channel that is located intracellularly and therefore not easily acces-
sible. This includes assays using isolated SR vesicles (e.g. [2,3]), single
RyR channels reconstituted into lipid bilayers (e.g. [4–9]), perme-
abilized cardiomyocytes [10,11], but also various biochemical tech-
niques (e.g. see [12,13]). Cellular ultrastructural and co-localization
information has been obtained with immunocytochemistry and
electron tomography [14,15] and structure on the molecular level
has been assessed with cryo-electron microscopy [16,17].se II; CICR, Ca2+-induced Ca2+ release; CPVT, catecholaminergic polymorphic ventricular
e oxygen species; RNS, reactive nitrogen species; NOX, nicotinamide adenine dinucleotide
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go several of the numerous known posttranslational modiﬁcations and a
number of reports have provided evidence for functional consequences
resulting from some of these modiﬁcations. These data were frequently
obtained in artiﬁcial experimental systems and under conditions far
away from the natural environment of the RyRs. Therefore, it often
remained unclear whether and how these observations on or near the
molecular level would translate into intact and living cardiomyocytes
and into the entire organ or organism [18].
Some time ago it became practical to closely examine RyR function
in-situ and within its native environment, which means inside living
cells. This has become possible because of groundbreaking develop-
ments of technologies to faithfully image subcellular and microdomain
Ca2+ signals with appropriate spatial and temporal resolution. These
developments were signiﬁcantly driven by the chemical synthesis of
bright and kinetically fast ﬂuorescent Ca2+ indicators [19,20] and the
simultaneous advancements of laser-scanning confocal microscopy
combined with digital image acquisition and processing [21].
Since several excellent reviews cover many aspects of RyR post-
translational modiﬁcations on the biochemical and molecular level
[22–30], here wewill concentratemainly, but not exclusively, on recent
ﬁndings that have been obtained by examining RyR activity and cardiac
Ca2+ signaling on the cellular level, where the channels can be exam-
ined under conditions not far from their native environment. In partic-
ular, wewill focus on the consequences of a combined impact of several
posttranslational modiﬁcations and their mutual interactions during
physiological regulation of RyRs and during the development of cardiac
diseases affecting RyR function.
2. The ryanodine receptor
2.1. The RyR macromolecular complex
In mammals three RyR isoforms are known: the skeletal muscle form
RyR1, the cardiac RyR2 and themore broadly expressed brain formRyR3.
The cardiac RyR2 is a large macromolecular complex consisting of
a homo-tetramer with 4 subunits comprising a molecular mass of
565 kDa each, totaling 2.2 MDa (for review see [31]). This complex is reg-
ulated and modulated in numerous ways by ions (e.g. Ca2+, Mg2+, H+),
by small molecules (e.g. ATP, cADPR) and by proteins (e.g. sorcin,
calstabin2, junctin, triadin). Important for this review, themacromolecu-
lar complex is also connected to protein kinase A (PKA), phosphatases
(e.g. phosphatase 1 and 2A) and phosphodiesterase (PDE4D) which are
tethered to the channel and held near their target sites by means of
anchoring proteins [32,33]. This allows for a tight and spatially conﬁned
homeostatic regulation of the balance between PKA-dependent RyR
phosphorylation and phosphatase dependent dephosphorylation. Ca2+/
calmodulin dependent kinase II (CaMKII) was also found to be associated
with the RyRs, but the nature and target speciﬁcity of this connection are
less clear [34]. On the RyR itself, a number of phosphorylation sites
have been identiﬁed (see Section 3). Furthermore, the RyR complex com-
prises several free cysteines that can be subject to reversible oxidative
modiﬁcation (see Section 4).
2.2. The Ca2+ signaling microdomain in the vicinity of the RyRs
In cardiacmuscle, a large fraction of the RyRs are organized in dyads,
where the SR membrane contains a cluster of 30–250 RyRs [35] and
comes in close contact (gap of ~15 nm) with the T-tubular membrane,
which harbors the voltage-dependent L-type Ca2+ channels. Opening
of one ormore L-type channels can activate CICR via several RyRswithin
a cluster. The tiny SR Ca2+ release generated by these few opening chan-
nels gives rise to a Ca2+ spark, an elementary Ca2+ signaling event,
which can be detected and analyzed using confocal imaging of Ca2+ sen-
sitiveﬂuorescence indicators (for reviews see [36,37]). During eachheart
beat, a large number of Ca2+ sparks are activated simultaneously,summing up to form the cardiac Ca2+ transient for the activation of con-
traction. Ca2+ sparks and even smaller Ca2+ release events, Ca2+ quarks,
can also occur spontaneously, for example during diastole [38,39]. Spon-
taneous Ca2+ sparks and Ca2+ quarks are considered to occur accidental-
ly and partly underlie the SR Ca2+ leak. Accidental spontaneous Ca2+
sparks do not normally trigger larger Ca2+ signals, such as Ca2+ waves,
and are therefore not arrhythmogenic. Eventless or “quarky” SR Ca2+ re-
lease through single (or very few) RyRswas recently proposed to contrib-
ute substantially to the leak [38–42]. However, under conditions of SR
Ca2+ overload and in circumstances which sensitize the RyRs, single
Ca2+ sparks can initiate Ca2+ waves traveling along the myocytes in a
saltatory fashion from sarcomere to sarcomere [43–46]. These Ca2+
waves have a substantial arrhythmogenic potential, since they are
able to initiate Ca2+ activated currents, such as the Na+–Ca2+ ex-
change current (INCX), which in turnmay depolarize the cardiomyocyte
to generate a delayed afterpotential (DAD) and even trigger premature
action potentials.
2.3. Ca2+ dependent activation and inactivation of the RyRs
The open probability of RyRs depends steeply on the cytosolic Ca2+
concentration, whereby Ca2+ is thought to bind to the RyR activation
site [47]. The increase of the RyR open probability subsequent to
openings of L-type Ca2+ channels and entry of Ca2+ into the dyadic
cleft is the main mechanism for activation of CICR during physiological
activity. The Ca2+ concentration prevailing in the dyadic cleft can only
be estimated with computer models at present [48], thus we use
“Ca2+ sensitivity” of RyRs as a descriptive term. In any case, the Ca2+
sensitivity of the RyRs in-situ is low enough to ensure independent
activation of adjacent Ca2+ spark sites, to allow for the regulation of car-
diac Ca2+ signals by virtue of local control and recruitment of Ca2+
sparks. The Ca2+ sensitivity of the channels for this type of activation
is known to depend on a number of modulators as mentioned above,
but also on several regulatory or disease-associated posttranslational
protein modiﬁcations (see Sections 3 and 4). Inactivation of the RyRs
and termination of the Ca2+ sparks in-situ are less well understood
and are the focus of signiﬁcant ongoing research efforts. One proposed
mechanism is based on the regulation of the RyRs by the Ca2+ concen-
tration inside the SR. Thereby, lowering the SR Ca2+ concentration dur-
ing a spark would make the RyRs insensitive for Ca2+ on the cytosolic
side of the channels, which causes their deactivation. Based on observa-
tions in SR vesicles, RyRs in lipid bilayers and cells overexpressing
calsequestrin, deactivation has been suggested to occur via a retrograde
signal mediated by allosteric interactions between calsequestrin (acting
as the Ca2+ sensor) and junctin and/or triadin and the RyR [2,8,49,50].
This mode of spark termination could be stabilized by a reinforcing
mechanism that has beenproposed recently based onmodel predictions.
The local SR depletion and subsequent decay in Ca2+ release ﬂux from
the SR during a Ca2+ spark may contribute to the self-termination,
because of the resulting decline of the dyadic Ca2+ concentration [51].
Other proposedmechanisms for spark termination include Ca2+ depen-
dent inactivation of the RyRs [52], but up to 100 μM cytosolic Ca2+ no
RyR inactivation was observed in permeabilized cardiomyocytes [53].
Another mechanistically attractive possibility is stochastic attrition,
where the probabilistic simultaneous closure of all RyRs in one cluster
would interrupt their mutual activation by CICR within the dyadic cleft
[54]. When all channels close, the very high dyadic Ca2+ concentration
drops to low cytosolic levels within a few milliseconds [48]. However,
the probability of all channels to be closed simultaneously is quite low
given the estimated number of RyRs in a cluster [35], unless their gating
is partly coupled [55].
The Ca2+ release termination mechanism mediated by lowering
of the SR luminal Ca2+ concentration and deactivation of the RyRs
could also be important under conditions of SR Ca2+ overload, the
opposite of the depletion during a Ca2+ spark and CICR. By sensitizing
the RyRs for Ca2+ on the cytosolic side, elevations of intra SR Ca2+
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(SOICR) and arrhythmogenic Ca2+ waves [46,56].
3. RyR phosphorylation
Asmentioned above, themechanism and functional consequences of
RyR phosphorylation have attracted much recent attention. Fig. 1 shows
a summary of the involved pathways. Interest in this issue was inspired
by a report suggesting that PKA dependent “hyperphosphorylation” of
RyRs could occur during heart failure (HF) thereby aggravating this
condition. Hyperphosphorylation was proposed to promote the Ca2+
sensitivity of RyRs resulting in elevated open probability. This in turn
would cause a substantial diastolic SR Ca2+ leak, which could contribute
to low SR Ca2+ content, smaller Ca2+ transients and hence weak
heart beat [12]. Using mainly biochemical and molecular biology ap-
proaches, serine 2808 and 2030 on the RyR have been identiﬁed as
possible phosphorylation sites for protein kinase A (PKA), and serine
2814 for CaMKII. However, the speciﬁcity of these sites for the men-
tioned kinases remains a disputed issue [12,57–59] and additional
sites are likely to exist [60]. Moreover, a ﬁerce controversy revolves
around the functional consequence and pathophysiological rele-
vance of the phosphorylation at these sites [61,62]. This debate
may result from differences in experimental approaches, methods
and tools, but also from variations of the particular animal and
disease models.
3.1. Phosphorylation by CaMKII
The picture which emerges from the literature seems to be more
clear for the consequences of CaMKII activation which leads toFig. 1. Modulation of the ryanodine receptor (RyR) by Ca2+ and phosphorylation. Ca2+ inﬂu
sarcoplasmic reticulum (SR), a process referred to as Ca2+ induced Ca2+ release or CICR, lead
SR Ca2+ ATPase (SERCA) and the sarcolemmal Na+–Ca2+ exchanger (not indicated). After CI
re-establishing diastolic Ca2+ levels. The sensitivity of RyR toward activating Ca2+ is m
Gs-protein-mediated activation of adenylyl cyclase (AC) and further cAMP-dependent activatio
at S2808, possibly inducing dissociation of calstabin 2, and at S2030, but also modulates the LT
cytosolic Ca2+ levels activate CaMKII, whichdirectly phosphorylates RyR at S2814. Similar to PK
homeostasis.phosphorylation of serine 2814 on the RyR and possibly other sites
[60,62], among many collateral targets. CaMKII activity seems to pro-
duce quite consistent functional changes of the RyRs that are reconcil-
able with the general prediction over a wide range of experimental
settings and approaches, extending from single channel experiments
to cellular Ca2+ signaling and a variety of transgenic animals. In single
channel experiments the open probability of the RyRs was generally
found to be increased upon phosphorylation by CaMKII [63] (but see
[64,65]). In isolated cardiomyocytes activation of CaMKIIwas associated
with an increase of the Ca2+ spark frequency [66]. Transgenic mice
overexpressing the cardiac isoform of CaMKII showed a marked hyper-
trophy, altered expression and phosphorylation levels of several
proteins involved in Ca2+ signaling. Despite lower SR Ca2+ content,
the cells also showed elevated Ca2+ spark frequencies, leading to
pronounced SR Ca2+ leak and a susceptibility for arrhythmias [67,68].
Ablation of CaMKII resulted in a protection of the animals from cardiac
hypertrophy, possibly mediated by the unavailability of CaMKII signal-
ing in the pathways of excitation–transcription coupling [69,70]. To
obtain further insight into the functional role of serine 2814 on the
RyR several mouse models were engineered to speciﬁcally scrutinize
this site. In one animal serine 2814 was replaced by an alanine, which
removes its capability to become phosphorylated by CaMKII (S2814A
mouse). Hearts of these animals and cardiomyocytes isolated from
them showed blunted force–frequency relationships [71] and the
mice were protected from arrhythmias induced by tachypacing
after being subjected to transverse aortic constriction (TAC) to induce
hypertrophy and failure [72]. Conversely, the S2814D RyR, where serine
is replaced by aspartic acid, mimics constitutive CaMKII dependent RyR
phosphorylation and increases the open probability of the channels
in bilayer experiments. Cardiomyocytes isolated from S2814D micex via the L-type Ca channel (LTCC) activates the RyR and triggers Ca2+ release from the
ing to myocyte contraction. The levels of free cytosolic Ca2+ are tightly regulated by the
CR and contraction, the Ca2+ store is reﬁlled by pumping Ca2+ back into the SR thereby
odulated by phosphorylation. Stimulation of the ß1-adrenoreceptor (ß-AR) leads to
n of PKA. PKA can directly phosphorylate RyR at several phosphorylation sites, presumably
CC and SERCA function, the latter by phosphorylation of phospholamban (PLB). Increased
A, CaMKII also phosphorylates PLB and the LTCC leading to global changes inmyocyte Ca2+
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increased by CaMKII activation [72] and themice developed a propensi-
ty for arrhythmias and sudden cardiac death when stressed with
catecholaminergic challenges or tachypacing subsequent to TAC.
Taken together, these and numerous other studies draw a picture
whereby in the short-term CaMKII dependent phosphorylation substan-
tially modiﬁes RyR function, cardiac Ca2+ signaling and EC-coupling.
Overall, these signaling systems seem to become boosted, more active
and Ca2+ sensitive but less well controlled, from the molecular to the
cellular and organ level. Thus, CaMKII has been considered as a treat-
ment target for multiple short term and long-term cardiac conditions
that are associated with disturbances of Ca2+ signaling and CaMKII
activation [73–76].
3.2. Phosphorylation by PKA
PKA dependent phosphorylation and “hyperphosphorylation” of
the RyRs at serine 2808 during heart failure (and in a transgenic
mouse model overexpressing the catalytic domain of PKA in the
heart) have been proposed to dissociate the stabilizing protein
calstabin 2 (a.k.a. FKPB-12.6) from the RyR macromolecular complex,
a sequence of events that is suggested to be followed by major
functional changes of the channels resulting in diastolic Ca2+ leak,
SR Ca2+ depletion and weak heart beat [12,77]. Obviously, this
mechanism could be very important both for the physiological
regulation of the channels during stress as well as for their patho-
physiological malfunctioning. Therefore, it has attracted substantial
research efforts from several laboratories. While in general phosphor-
ylation of the S2808 site has been conﬁrmed by various laboratories,
speciﬁcity for PKA of this site, the conditions under which phosphor-
ylation would occur and whether or not this leads to calstabin 2
dissociation have remained equivocal [57]. An additional PKA site
has been identiﬁed at serine 2030 [58,78]. On the single channel
level, functional changes after PKA-dependent phosphorylation have
been described some time ago [79,80]. On the cellular level, the
consequences of PKA-dependent RyR phosphorylation have been
more difﬁcult to pinpoint, partly because of the complex adjustments
of multiple signaling networks downstream the activation of PKA
in intact or permeabilized cells. Changes of Ca2+ spark parameters
indeed were observed upon application of cAMP in permeabilized
mouse cardiomyocytes, but were entirely attributable to the concom-
itant SERCA stimulation resulting from PLB phosphorylation, as they
were not present in cells isolated from PLB ablated mice, where
SERCA is already maximally stimulated [11]. Two-photon photolysis
of caged Ca2+ to artiﬁcially trigger Ca2+ sparks suggested changes
of RyR gating after β-adrenergic stimulation, since in resting Guinea
pig myocytes larger Ca2+ release events were observed despite a
decline of SR content [81]. However, when analyzing the frequency
of spontaneous Ca2+ sparks at rest, this was later found to most likely
depend on CaMKII activation [82].
Because of these difﬁculties to dissect the consequences of
β-adrenergic stimulation on RyR function, transgenic animals have
been engineered speciﬁcally targeting the serine 2808 site. Several
animal models have been created where this serine is replaced by
alanine, resulting in S2808A channels which can no longer be phos-
phorylated at this site [59,83]. Another model is the S2808D mice,
which have a modiﬁcation which corresponds to constitutively phos-
phorylated RyRs. Unfortunately, the generation of these animals has
not fulﬁlled the expectation to clarify the open issues, as the results
published in several reports have again been controversial. Initial
studies with the S2808A mice showed that the modiﬁcation was
very subtle, did not disturb normal cardiac function and the animals
had no overt phenotype. However, after myocardial infarction (MI)
these mice were protected from developing heart failure and from ar-
rhythmias induced by phosphodiesterase inhibition [59]. Reconstituted
S2808A channels did not show elevated open probability after MI, incontrast to those from WT mice (an observation which is puzzling by
itself, because the CaMKII phosphorylation site on these RyRs should
still be functional [72]). This difference on the molecular level was
proposed to be the underlying mechanism preventing SR Ca2+ leak,
weak heartbeat and the susceptibility to arrhythmias in S2808A mice.
In a different laboratory, a further S2808A mouse was engineered
and these animals were subjected to a pressure overload heart failure
model after TAC [83]. In this study, no obvious cardioprotection was
conferred to the animals by ablating the 2808 phosphorylation site.
Furthermore, no substantial differences between WT and S2808A
RyRs were present in the open probability and gating kinetics of
reconstituted channels. This study then examined Ca2+ signaling
and EC-coupling on the cellular level, including an analysis of Ca2+
sparks and waves. Again, no signiﬁcant differences were found
between the two groups of animals. These observations led the
authors to conclude that the serine 2808 site only has a limited role
in the pathogenesis of heart failure.
At present it remains unsettled why these apparently similar studies
led to essentially opposite conclusions. One has to consider that the used
disease models and the particular pathomechanisms activated in each of
them (e.g. pressure overload after TAC versus ischemia/inﬂammatory
disease without pressure overload but potentially more oxidative stress
[84]) could result in quite different outcomes, as has been observed in
another study investigating CaMKII dependent RyR phosphorylation
[85], or that the RyRs of the two engineered animals do not operate in
a perfectly identical way [86]. Alternatively, some of the resulting
functional modiﬁcations may be rather subtle, and can be compensated
by auto-regulatory features of the cardiac EC-coupling machinery [87]
and are therefore difﬁcult to detect.
Starting from the latter possibility, a detailed study was carried
out to examine SR Ca2+ release kinetics, their spatial synchronization,
and the improvement of this parameter by β-adrenergic stimulation
when the communication between L-type Ca2+ channels and RyRs
was challenged [88]. The reasoning for this approach was the notion
that these events occur at the very interface between the L-type
Ca2+ channels and the RyRs and might therefore reveal even subtle
changes. When this communication was tested by using very small
Ca2+ currents as triggers, substantial spatial desynchronization was
observed. This was resynchronized upon β-adrenergic stimulation in
the WT [89] but not in the S2808A cells. Furthermore, unlike WT cells,
Ca2+ wave propagation was not accelerated upon β-adrenergic stimu-
lation in S2808A cells. Together with the long delays observed in the
release synchronization, this suggested the possibility of an intra-SR
mechanism [46,56], whereby SR Ca2+ loading via SERCA would lead
to sensitization of the RyR from the luminal side, thereby pushing the
channel over the trigger threshold. The possibility of an intra-SR
mechanism was then conﬁrmed in reconstituted single RyR channels.
At high SR Ca2+ concentrations, and only under this condition, WT
channels indeed responded with a signiﬁcantly larger increase in
open probability upon PKA dependent phosphorylation than S2808A
channels. Regarding the ongoing controversy, the main conclusion
from these studies is that the effects of serine 2808 phosphorylation
are present but delicate and may be difﬁcult to detect when SR Ca2+
content is not controlled experimentally (e.g. in vivo, when the
auto-regulatory adjustments of SR Ca2+ content mentioned above
may compensate for small changes of RyR open probability).
Taken together it appears that the mechanisms and conse-
quences of PKA dependent RyR phosphorylation are less clear and
potentially more subtle than those mediated by CaMKII. Whether
and how these delicate changes translate into the in vivo situation
is difﬁcult to extrapolate and will require more research. In support
for this expectation, a recent cross-breeding experiment between
dystrophic mdx and S2808A mice indicated that the RyR mutation
confers signiﬁcant protection for cardiac disease manifestations
and progression of the dystrophic cardiomyopathy in these ani-
mals (see below) [90].
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4.1. RyR oxidation by ROS
Changes of the cellular redox state give rise to another category of
posttranslational RyR modiﬁcations, which do not only have a modu-
latory function but also play an important role in the development of
various cardiac diseases. The term “intracellular redox potential”
broadly describes the balance between reduced and oxidized proteins
within cells, which in turn is determined by the level of generation
and buffering of cellular reactive oxygen and reactive nitrogen species
(ROS/RNS). There are multiple sources of ROS/RNS within the cell
(see Fig. 2). They include but are not limited to NADPH oxidase
(NOX), xanthine oxidase (XO), mitochondria and nitric oxide synthase
(NOS). On the other end there are various cellular antioxidant
defense components such as catalase, superoxide dismutase, thio- and
glutaredoxins, glutathione peroxidase, glutathione, vitamins A, C and
E, etc.Under physiological conditions, the extent of ROS/RNS accumula-
tion is ﬁnely controlled by these scavenging and reducing mechanisms,
and at low concentrations ROS/RNS serve as important intracellular
messengers. An imbalance between generation of ROS/RNS and the
efﬁciency of cellular defense systems can lead to a transient or persis-
tent oxidative/nitrosative stress resulting in redox modiﬁcations of
various cellular proteins, including those involved in Ca2+ homeostasis.
The RyR is an important example, since it is known to be very suscepti-
ble to redoxmodiﬁcations. Each cardiac RyR tetramer contains a total of
364 cysteines [91]. In the presence of a physiological concentration of
one of the major cellular “redox buffers” glutathione (5 mM) about 84
of these cysteines are free. The sulfhydryl groups of these cysteines
are subject to reversible cross-linking, S-nitrosation (often referred to
as S-nitrosylation) and S-glutathionylation. Numerous studies of RyRs
incorporated in lipid bilayers convincingly showed that reversible
redox modiﬁcations signiﬁcantly affect the activity of RyR channels.Fig. 2. Redox-modiﬁcations of RyRs. Changes in the redox potential of the myocyte have be
RyR. The main sources for the production of reactive oxygen species (ROS) in cardiomyoc
mitochondrial electron transport chain (complex I through IV). ROS can glutathionylate fr
and subsequent RyR phosphorylation. Nitric oxide synthases (NOS) are mainly respons
cardiomyocytes, sarcolemmal endothelial NOS (eNOS), which co-localizes with caveolin
for the production of NO, causing S-nitrosation at free thiol groups of the RyR and many o
modiﬁcations of RyR function.Oxidative conditions generally increase the RyR open probability,
while reducing agents do the opposite (e.g. [91–94]). Therefore, the
functional consequence of a moderate cellular oxidative/nitrosative
stress could be immediate enhancement of Ca2+ release from the SR
in response to a given physiological trigger. This possibility has been
supported by experimentswith isolated SR vesicles (e.g. [91,95]). The in-
creased Ca2+ sensitivity of RyRs and subsequently larger Ca2+ transients
could have a positive inotropic effect on the cardiac function [96].
However, severe oxidative stress can cause irreversible and sustained ac-
tivation of RyRs [91], increasedCa2+ leak from the SR, decreased SRCa2+
load and ﬁnally a decline of beat-to-beat cellular Ca2+ transients with
contractile dysfunction. Such conditions are usually associated with or
even caused by the development of various cardiac abnormalities. There-
fore, the role of RyR redox modiﬁcations in cardiac pathophysiology is
currently under intensive investigation in multiple laboratories around
the world.
When the experimental gear was shifted from molecules and
vesicles towards studies of cells, organs and organisms, it became
obvious that the ﬁndings obtained from isolated RyR channels cannot
be translated to more complex biological systems without a critical
reevaluation. Besides the presence of various cellular sources for
ROS, redox modiﬁcation targets multiple intracellular sites including
major proteins involved in EC coupling and all of them need to be
considered in order to identify the link between each modiﬁcation
and the resulting changes of RyR function [97]. To discriminate
between correlative, adaptive and causal posttranslational RyR
modiﬁcations is often a daunting task.
Cardiac muscle has a substantial NOX activity (for reviews see
[98,99]). It has been reported that NOX2 is the predominant isoform
expressed in T-tubular and SR membranes of mature cardiomyocytes.
Therefore, it is strategically positioned to modulate the activity of the
RyRs. NOX is an enzyme that utilizes NADPH to produce superoxide
anion. NOX2 was found to be overexpressed and/or its activityen shown to have a serious inﬂuence on protein function, especially at the level of the
ytes are the sarcolemmal NADPH oxidase (NOX), the xanthine oxidase (XO) and the
ee cysteine residues on the RyR and also act in an indirect way via CaMKII activation
ible for the production of nitric oxide (NO) and reactive nitrogen species (RNS). In
-3 (Cav3) in caveolae, and RyR-associated neuronal nNOS are primarily responsible
ther proteins. Most likely, these mechanisms work synergistically and induce parallel
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history of atrial ﬁbrillation [102], and in hearts subjected to
tachycardiac preconditioning [103]. Although the exact mechanisms
of NOX activation under these pathological conditions remain
unclear, it was shown that ROS produced by NOX stimulates SR
Ca2+ release via at least two pathways: 1) direct oxidation or
S-glutathionylation of RyRs or 2) indirectly through CaMKII activation
[104] followed by phosphorylation of the RyRs. Reducing or ROS
scavenging compounds could generally mitigate or prevent the con-
sequences of oxidative stress in these experimental models. Another
widely recognized source of ROS production in cardiac myocytes is
mitochondria [105,106]. Mitochondria always generate a small
amount of ROS through leakage in the electron transport chain during
respiration. Under some pathophysiological conditions, such as
ischemia/reperfusion, ROS produced by mitochondria become the
main contributors to cellular oxidative stress. In this situation
mitochondrial Ca2+ overload and subsequently ROS overproduction
may trigger mitochondrial permeability transition, which in turn
boosts ROS production via ROS-induced ROS release mechanisms
[107,108]. There are also several reports indicating upregulation of
XO activity in experimental models of heart failure [109]. Further-
more, contractile function and myocardial efﬁciency in HF could be
improved by treating the animals with xanthine oxidase inhibitor
allopurinol [110,111]. Overall, regardless of the source of their
generation, ROS and subsequent oxidative modiﬁcations of RyRs
have been directly held accountable for augmented stretch-induced
Ca2+ responses and hypersensitive EC-coupling in dystrophic
cardiomyocytes [101,112–115] as well as in impaired Ca2+ signaling
in failing [116,117] and diabetic hearts [118,119].
4.2. RyR modiﬁcations by RNS
The twomajor isoforms of NO synthase (NOS) in cardiac myocytes
are eNOS and nNOS. They have a speciﬁc sub-cellular localization and
are possibly aimed at different targets in their microdomains, due to
the short range of NO diffusion. The eNOS isoform is localized in the
plasma membrane in caveolae through interaction with caveolin-3.
In healthy cardiac muscle nNOS is mainly located in the SR
membrane, linked to the RyRs. In failing or diseased hearts nNOS
may partly redistribute to the sarcolemma. Normally, the iNOS
isoform is not present in signiﬁcant amounts, but this may be differ-
ent during the development of cardiac diseases. NO produced by
these enzymes can bind to free thiol groups on various proteins,
including RyR, causing S-nitrosation and conformational changes.
Alternatively, NO can act via the cGMP dependent pathway and
activated PKG, a protein kinase which is thought to phosphorylate
the RyR at the S2814 CaMKII site, at least in vitro [60]. However,
whether this occurs in vivo is presently unclear.
An important role for direct RyR nitrosation in cardiac EC-coupling
and Ca2+ signaling was suspected already some time ago (for review
see [96]), when it was found that the stretch-induced enhancement
of cardiac Ca2+ signals and elevation of Ca2+ spark frequency were
blunted in the presence of L-NAME, an unspeciﬁc inhibitor of all
NOS isoforms [120]. The effect of stretch could be mimicked by
adding the NO donor SNAP, which nearly doubled the Ca2+ spark
frequency. Additional studies reported that NO could have diverse
actions, depending on the preexisting extent of β-adrenergic stimula-
tion. NO donors increased the Ca2+ spark frequency in a cGMP inde-
pendent way at low (10 nM) concentrations of ISO, presumably by
RyR nitrosation (but other mechanisms were not excluded) [121].
At 1 μM ISO a decrease of the spark frequency was observed, however
this was accompanied (or caused) by a reduction of the SR Ca2+
content. In nNOS−/−mice, but not in eNOS−/−mice, hyponitrosation
of the RyRs was observed, indicating that the structural proximity
between nNOS and RyR may be functionally relevant. Interestingly,
these RyRs exhibitedmore extensive oxidative modiﬁcations, thoughtto lead to elevated SR Ca2+ leak [122]. Thus, constitutive RyR
S-nitrosation in WT animals may confer some protection of the
channels against more severe oxidative modiﬁcations. This may be
important in various diseases, where changes of the nitrosation
have been implied in their pathology, but also in conferring some
cardioprotection [123]. However, in another study with myocytes
from nNOS−/− mice, Ca2+ spark frequencies and the SR Ca2+ leak at
a given Ca2+ load were found to be reduced, and both could be
normalized (i.e. increased) by exposure to an NO donor [124]. In line
with these ﬁndings, RyRs were hypernitrosated in cardiomyocytes
with upregulated nNOS activity and this was paralleled by increased
SR Ca2+ leak and elevated fractional Ca2+ release [125]. Taken
together, and considering the caveats when interpreting experimental
data obtained from transgenic animals, these ﬁndings indicate that,
depending on the conditions (e.g. on the extent of oxidative stress),
nNOS signaling can also increase RyR activity in cardiac muscle, either
directly or indirectly.
In one disease related study the extent of RyR nitrosation was quan-
tiﬁed inmicewith dystrophic cardiomyopathy and found to be increased
around 4–5 fold [126], while PKA dependent RyR phosphorylation was
not signiﬁcantly elevated. This was accompanied by a doubling of the
frequency of spontaneous Ca2+ sparks and a propensity for arrhythmias.
The extent of RyR oxidation and CaMKII-dependent RyR phosphoryla-
tion was not assessed directly, but the protective effect of N-acetyl
cysteine (NAC) suggests an important role of oxidative stress in
dystrophic cardiomyopathy, as reported earlier [100,101].
The general concept which emerges from these partly controversial
studies, although rather diffuse, suggests that the reciprocal interac-
tions between RyR modiﬁcations resulting from ROS and RNS and
their functional outcome are very complex and not yet fully understood.
While some observations suggest quite synergistic actions, in other
experimental settings more competitive effects between ROS and RNS
modiﬁcations become apparent. Interactions between ROS and RNS
are possible in various ways, for example through their tightly
connected chemistries (e.g. superoxide and NO can combine to form
peroxynitrite [127]) or by competing for the same thiols on the RyR. A
further complication in the interpretation of the experimental data may
arise from the ﬁnding that RyR2 is nitrosated via S-nitrosoglutathione
(GSNO) and not by NO directly [94]. Further, most experiments were
carried out at ambient oxygen pressure (~150 mm Hg), but in the tissue
there ismuch less oxygen (~10 mm Hg). The degree of oxidation and the
function of the cardiac RyR aremodiﬁed by ambient O2 [94]. In any case, it
seems that the precise balance between ROS and RNS is important,
and that a NO/ROS disequilibrium can lead to abnormal RyR channel
behavior [128].
5. Cross-talk between redox modiﬁcations and phosphorylation
in disease
Recently, a number of studies have been carried out in a variety of
cardiac disease models, focusing on modiﬁcations of RyR function and
the conceivably underlying posttranslational modiﬁcations. A common
ﬁnding in many of these studies was a sequential (i.e. during disease
development) or simultaneous presence of several posttranslational
RyR modiﬁcations. While such a pattern could result from parallel but
unrelated changes of the involved pathways, it seems more plausible
that these modiﬁcations are not independent from each other. There
are numerous possibilities for signiﬁcant cross-talk and synergisms
among these signaling pathways such as ROS/RNS, phosphorylation
and Ca2+ signals, from the origin (receptor or source of the signal)
down to the target, the RyR itself (for reviews see [129,130]). In one
scenario, boosting the Ca2+ transient by phosphorylating various
Ca2+ signaling proteins may elevate mitochondrial Ca2+ content,
followed by an increased mitochondrial metabolism and ROS produc-
tion [105]. Mitochondrial ROS can further augment the Ca2+ signals
by oxidizing multiple Ca2+ signaling proteins, as described above, but
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to the stimulation by the larger Ca2+ transients themselves and will
lead to extra protein phosphorylation [104], thereby establishingmulti-
ple and coupled positive feed-back loops, which further amplify these
signals [131]. Moreover, receptors and enzymes involved in the gener-
ation, modulation and termination (e.g. phosphatases, phosphodiester-
ases, ROS scavengers, SNO reductases) of these associated signals are
often regulated via other functionally interconnected pathways. For
example, β-adrenergic responsiveness is regulated by NO, creating a
link between NO, phosphorylation and Ca2+ signals [132]. In turn, the
activity of NOSes is Ca2+ sensitive [133]. The eNOS isoform (but not
nNOS) is stimulated by ROS [134]. Most likely, many more direct and
indirect possibilities for cross-talk between these pathways exist
within cells.
Interactions between RyR oxidation and phosphorylation have
been studied in dystrophic cardiomyopathy, a disease that combines
a high degree of oxidative stress and excessive Ca2+ signals after
mechanical stress, resulting from the lack of the protein dystrophin
[101]. In one example, a cross-breeding approach has been applied
to test for rescue from this disease by eliminating not the main
pathomechanism, but another step in the vicious cycle [90].
Dystrophic mdx mice were crossed with RyR-S2808A mice, which
carry RyRs that cannot be phosphorylated at this site. Ablation of
this phosphorylation site protected these animals, even though not
the main pathomechanism was targeted, but rather one of the other
steps in the positive feed-back loop. Unlike mdx mice, these animals
did not develop cardiac hypertrophy with ﬁbrosis and showed
improved cardiac function. Further, they were protected from
isoproterenol-induced arrhythmias and SR Ca2+ leak. These ﬁndings
suggest that PKA dependent RyR phosphorylation contributes to the
abnormal Ca2+ homeostasis in dystrophic cardiomyopathy. Interest-
ingly, and in apparent contrast to these ﬁndings, another study was
not able to detect signiﬁcant PKA dependent RyR phosphorylation
inmdxmice [126]. However, more recent studies suggest that the dis-
ease phenotype and the pattern of RyR posttranslational modiﬁca-
tions change in the course of dystrophic cardiomyopathy, and other
diseases as well. Unlike oxidative stress and CaMKII activation, RyR
phosphorylation by PKA seems to become important only at later
stages of the disease, and is associated with elevated SR Ca2+ leak
and reduced Ca2+ content [115].
6. Possible clinical relevance
Amultitude of cardiac diseases are accompanied by acute or chronic
hyperadrenergic states and/or oxidative cellular stress which can
initiate vicious cycles and pathomechanisms involving RyR posttransla-
tional modiﬁcations similar to those described above. Since phosphory-
lation, as well as oxidation and elevated Ca2+ concentration will
increase the RyR open probability, the CICR mechanism may become
very sensitive and unstable. To what extent these multiple changes
and the concomitant posttranslational RyRmodiﬁcations exert additive
effects andwhether they progress rapidly or slowly during the develop-
ment of a given disease is not yet established and remains to be inves-
tigated. However, a number of recent experimental studies on the
cellular level are in line with this possibility. Examples for diseases
where posttranslational RyR modiﬁcations have been reported are
congestive heart failure [116], dystrophic cardiomyopathy [101],
diabetes [119], ischemia/reperfusion [135] and atrial ﬁbrillation [136].
However, the clinical relevance of the presented experimental ﬁndings
in general and the impact of the identiﬁed pathomechanisms and
suspected cross-talk pathways in particular can ultimately only be
conﬁrmed in clinical trials. In such future pilot studies multipronged
therapeutic strategies would need to be compared with established
treatments targeting only one mechanism. Nevertheless, some of the
animal studies carried outwith various diseasemodels are already fairly
developed and can provide a solid foundation on which to base futureclinical trials, possibly with studies in human cardiomyocytes and in
larger animals as intermediate steps. Based on the available data a few
disease entities have been identiﬁed in which posttranslational RyR
modiﬁcations seem to make a substantial contribution to disease
progression. One category of examples is a variety of disease models
leading to heart failure (e.g.myocardial infarction, transverse aortic con-
striction (TAC), artiﬁcial tachypacing, dystrophic cardiomyopathy). In
these entities both, oxidative RyR modiﬁcations and CaMKII (and possi-
bly PKA) dependent RyR phosphorylation have been found to be present
concurrently, but in various proportions [85,115,116,126,137,138]. The
concomitant destabilization of the RyRs may also favor or underlie the
occurrence of various forms of arrhythmias, initiated by diastolic Ca2+
release leading to delayed afterdepolarizations and extrasystoles. Not
unexpectedly, the arrhythmogenicity of phosphorylated RyRs also ap-
pears to be instrumental in some forms of atrial ﬁbrillation [139–142].
Another layer of complexity is added to the intricatemutual interac-
tions of all the posttranslational modiﬁcations discussed above in
patients carrying a mutation of the RyR2 [143,144]. These mutated
channels often exhibit destabilized gating behavior, possibly arising
from altered interaction (i.e. zipping) of RyR channel domains
[145,146]. Many of these patients are prone to stress-induced arrhyth-
mias, manifesting themselves as catecholaminergic polymorphic
ventricular tachycardias (CPVTs), potentially leading to sudden cardiac
death. Cell lines and transgenic animals have been engineered express-
ing RyRs harboringmutations thatwere identiﬁed in familieswith CPVT
patients [147–150]. These animals replicate the human disease pheno-
type and serve as disease models to investigate pathomechanisms
arising from RyR mutations and to develop therapeutic approaches. In
these disease models, arrhythmias could be provoked by tachypacing
and/or by β-adrenergic stimulation. In cellular experiments, these
cardiomyocytes exhibited elevated Ca2+ spark frequencies, a propensi-
ty for diastolic Ca2+ waves with delayed after-depolarizations and
reduced wave thresholds. These are all signs for disturbed channel
gating with a predisposition towards abnormal Ca2+ sensitivity (cyto-
solic or SR luminal) of mutated channels. In summary, the phenotypes
resulting from RyR mutations share many features with the functional
consequences of the posttranslational modiﬁcations discussed above.
While it iswell established that physical or emotional stress can prompt
CPVTs in patients harboring cardiac RyRmutations, it is so far unknown
how stress exactly triggers these arrhythmias. Are they provoked by ad-
ditional RyR sensitization originating from PKA or CaMKII dependent
RyR phosphorylation? Or are they the result of the concomitant stimu-
lation of the SERCA after PLB phosphorylation, leading to elevated SR
Ca2+ loading? Or is it the combination of these two possibilities
which is particularly detrimental?
7. Conclusion and outlook
While we start to understand the consequences of various post-
translational RyR modiﬁcations on the molecular level, we also devel-
op the awareness for the extraordinary complexity of this issue on
the cellular and organ level. This partly results from the multiple
crosstalks and interactions of the various signaling pathways and
their intertwined positive and negative feed-back loops. A large
amount of research will thus be required to address the question
whether all the regulatory and/or pathophysiologically important
mechanisms changing RyR function behave in additive, competitive
or mutually exclusive ways. To answer these and many similar ques-
tions relevant for other cardiac conditions, it needs to be understood
in more detail, on the molecular level, how these modiﬁcations
interact to bring about functional change. These ﬁndings then need
to be integrated into the more complex situation of intact cells,
organs and organisms, to determine their physiological and clinical
relevance. Based on the presently available literature, only partly
discussed above, one is inclined to predict that such interactions
exist and are very important. Understanding these interactions will
873E. Niggli et al. / Biochimica et Biophysica Acta 1833 (2013) 866–875lay the foundation for the development of mechanism based thera-
pies, potentially targeting several synergistically acting mechanisms
simultaneously.
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